ReviewBritish journal of cancer2021
Cytotoxic CD8
Review in British journal of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,036 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,036 citing papers in PubMed, 2 syntheses or guidelines pooled it, 1,613 citations in OpenAlex.
- The mechanism of breast cancer stem cells and tumor microenvironment promoting radioresistance in breast cancer and its intervention strategies.Frontiers in immunology · 2026Pooled it
- The tumour microenvironment in paediatric rhabdomyosarcomas: a systematic review.Carcinogenesis · 2025Pooled it
- Tumor-Immune-On-Chip to Evaluate Pathophysiological Feature of T Lymphocytes Expanded from Patient Tumors and Lymph Node Tissues.Cancer medicine · 2026Trial
- DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8Oncoimmunology · 2026Article
- The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.Human vaccines & immunotherapeutics · 2026Review
- Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies.Nature reviews. Urology · 2026Review
- Prognostic value of neutrophil-to-lymphocyte ratio in nasopharyngeal carcinoma: a systematic review and meta-analysis of 30 cohorts through June 30, 2026.Translational cancer research · 2026Article
- Ectopic integrin β1 overproduction by squamous carcinoma cells contributes to immune evasion-associated metastasis.Cancer letters · 2026Article
- Myeloperoxidase promotes a tumorigenic microenvironment in non-small cell lung cancer.Redox biology · 2026Article
- Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte-mediated cancer immunotherapy.Science advances · 2026Article
- Lymphocytic Choriomeningitis Virus Bearing GPC Mutations for Enhanced Tumor Tropism and Strong Anti-Tumor Activity.Viruses · 2026Article
- Physical Exercise in Immunotherapy.Sports medicine - open · 2026Review
- Focal therapeutic conditions matter: How energy affects antigen presentation and T cell activation.Bioengineering & translational medicine · 2026Article
- The theory of the inflammatory ecosystem.Science China. Life sciences · 2026Review
- Cardiotoxicity of T cell immunotherapies.Nature reviews. Cardiology · 2026Review
- Potassium channels in cancer: from hallmarks to therapeutic targeting.Journal of physiology and biochemistry · 2026Review
- PGK1 epigenetically silences STING via DNMT1 and its knockdown synergizes with STING agonists in pancreatic cancer.Acta pharmacologica Sinica · 2026Article
- Manganese-potentiated cGAS-STING activation with ATM/PRMT5 inhibition remodels the immunosuppressive microenvironment in osteosarcomaBioactive materials · 2026Article
- Understanding the Lymph Node Microenvironment in Metastatic and Non-Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review.Journal of personalized medicine · 2026Review
- Kdm2a histone demethylase ablation restores anti-tumor immunogenicity in liver cancer.British journal of cancer · 2026Article
976 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The functions of, and interactions between, the innate and adaptive immune systems are vital for anticancer immunity. Cytotoxic T cells expressing cell-surface CD8 are the most powerful effectors in the anticancer immune response and form the backbone of current successful cancer immunotherapies. Immune-checkpoint inhibitors are designed to target immune-inhibitory receptors that function to regulate the immune response, whereas adoptive cell-transfer therapies use CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.